Lupin Limited · NSE:LUPIN
Lupin — Q1 FY24 Earnings Presentation
18 slides from Lupin's earnings presentation, Aug 5, 2023
Slide 1: Exchange filing cover letter: Investor Presentation Q1 FY24
August 4, 2023 BSE Limited Department of Corporate Services, P. J. Towers, Dalal Street, MUMBAI - 400 001. National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051. Dear Sir/Madam, Sub: Investor Presentation Q1 FY24. Pursuant to Regulation 30(2)
Slide 2: Investor Presentation Q1 FY24
Investor Presentation Q1 FY24 August 4, 2023
Slide 3: Q1 FY24 Performance
Q1 FY24 Performance
Slide 4: Q1 FY24: Key Growth Metrics
Q1 FY24: Key Growth Metrics Continued focus on meaningful and profitable growth Key Metrics Business Performance INR mn India North America 47,421 mn 16,384 mn 15,905 mn Revenue 10% YoY 11% QoQ 57% YoY 3% QoQ 32% YoY 10% QoQ 8,791 mn Growth Markets EMEA EBITDA1 18.5% 4,066 mn 3,987 mn Margin 4% YoY
Slide 5: Q1 FY24: Key Developments
Q1 FY24: Key Developments Significant positive momentum on all fronts Financials Pipeline Sales and Adj. EBITDA* Margin gTiotropium US FDA, gDarunavir With 180 TGA and day Trajectory approved Canada launched exclusivity 50,000 47,421 20.0% 40,912 42,446 43,303 Compliance 40,000 36,040 15.0% 30,000 1
Slide 6: Q1 FY24 Financial Snapshot
Q1 FY24 Financial Snapshot Sales Mix (ex NCE income) Key Financials INR in mn Revenue (INR mn and %) North Q1 FY24 Q4 FY23 Q1 FY23 India, 16,384, 35% America, 15,905, 34% Sales 47,421 43,303 36,040 NCE 47,421 Income, mn Growth 2,053, 4% Markets, EBITDA 8,791 6,150 2,379 4,066, 9% API, 3,371, 7% ROW,
Slide 7: India: Bouncing Back
India: Bouncing Back India Prescription business has grown >13% ex Leveraging therapy leadership by adding 6 Cidmus and NLEM impact in Q1 FY24 new divisions India Sales (INR mn) 15,841 16,384 #2 rank #3 rank #3 rank 14,920 15,213 14,786 Respiratory Diabetes Care Cardiac • ~7,000 Total MEs1 and ~9,10
Slide 8: North America: Gaining Momentum
North America: Gaining Momentum Leadership: Delivering 5.2% New product sales driving Growing Respiratory TRx Gx volume of the U.S.1 US growth ($ mn) portfolio 159 177 175 181 #3 #1 21.8% 41.0% in the US1 in 41 products2 Albuterol Arfomoterol market share market share Maintaining Top 3 in 109 Q2FY23
Slide 9: Other Markets: Key Highlights
Other Markets: Key Highlights Other Key Markets driving growth Emerging Markets: Steady growth • Luforbec, Namuscla and • BRL 75 mn sales in Q1 FY24 levetiracetam growing (growth of 30% YoY) driven by EU Brazil ibuprofen & acquired portfolio • Completed Medisol acquisition in France • In reference m
Slide 10: Key Financial Metrics: Quarterly Trend
Key Financial Metrics: Quarterly Trend 2,000 10.0% R&D (INR mn) Capex (INR mn) Net debt/ Equity 9.0% 3,900 3,679 15.0% 1,540 1,555 1,502 3,600 3,376 8.0% 13.0%1,500 0.27 3,300 2,896 3,050 7.0% 0.25 3,000 11.0% 1,171 2,700 6.0% 2,400 9.0% 1,000 0.20 5.0% 2,100 7.0% 1,800 8.3% 7.8% 4.0% 1,500 6.8% 7.0
Slide 11: P&L Highlights Q1 FY24
P&L Highlights Q1 FY24 QoQ YoY Amount in INR mn Q1FY24 % of Sales Q4FY23 % of Sales Q1FY23 % of Sales Growth Growth Sales 47,421 100.0% 43,303 100.0% 9.5% 36,040 100.0% 31.6% Other operating income 719 1.5% 998 2.3% -27.9% 1,399 3.9% -48.6% Total revenue 48,141 101.5% 44,301 102.3% 8.7% 37,438 103.9
Slide 12: Lupin at a Glance
= mse " ; | b Bh ee LUPIN Lupin ata Glance
Slide 13: Lupin Today
Lupin Today Operating from a position of strength Global Presence Local Leadership Geographically Diverse (FY23 Sales) 13th Largest in India Pharma Largest Generic 3 rd the US 6th Market 37% INDIA 8% Developed Company (by prescriptions3) Markets (by sales3) (by sales1) 32% Largest Largest South US $
Slide 14: Vision
Vision A pharmaceutical company focused on delivering high quality medicines to patients around the world Global Other United Developed India Region Emerging API States Markets Markets Evolving portfolio and Global operational Delivering innovative pipeline in Complex Global reach and scale efficien
Slide 15: Lupin's ESG goals
Lupin’s ESG goals In the context of double materiality, our goals are aligned to material topics impacting both enterprise value & environment / society Product Accessibility Innovation Regulatory Compliance, Patient Environmental and Affordability Management Quality, and Patient Safety Centricity S
Slide 16: ESG: Progress against goals in FY22
ESG: Progress against goals in FY22 For our other material topics where we had taken targets in FY22 Targets Progress in FY23 Targets Progress in FY23 Undertaking detailed Kick-started Supplier 15% women employees 8.79% of permanent ESG audits of 100% of Assessment. We assessed across all business u
Slide 17: Lupin – Awards and Accolades
Lupin – Awards and Accolades Organizational Awards Leadership and Other Awards • ATD (Association of Talent • Vinita Gupta, named among India’s 20 Most Influential Women in Development) BEST Award Healthcare by 2022 BW Healthcare World • ‘Factories of the Future’ at the • Goa and Nagpur awarded Gold
Slide 18: Thank You
youtube.com/c/LupinGlobal twitter.com/LupinGlobal linkedIn.com/company/lupin facebook.com/LupinWorld/ Thank You Registered Address 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai – 400055, India Phone: +91 22664 02323 | Fax: +91 22664 02051 | www.lupin.com